Is Mounjaro Going Up in Price in the UK?

What Eli Lilly's list-price increase actually changed — and when

In August 2025, Eli Lilly announced a significant revision to Mounjaro's UK list pricing, taking effect from 1 September 2025. Before that date, the highest-dose pen carried a list price of around £122. Afterwards, the same pen was listed at around £330. That is not a misprint. The change was widely reported in the press and acknowledged by Lilly UK directly. If you are wondering when Mounjaro's price went up and what the timeline looked like, older price comparisons you find online predate this shift and are no longer reliable.

It matters to understand what a list price is: it is the baseline from which private pharmacies set their own fees, accounting for dispensing costs, clinical staffing, safety infrastructure and delivery. No private provider is obliged to pass the list price straight to patients, but all are constrained by it. This is why reported private market prices now typically run from around £149 at the lower doses up to approximately £375 per monthly pen at the highest, figures that have moved considerably from where the market sat before September 2025.

The dose you are prescribed also determines the cost. Treatment starts at 2.5 mg (a tolerability step designed to let your system adjust, not yet the therapeutic phase) and titrates upward at roughly four-week intervals under prescriber guidance. A patient on 5 mg will pay less than one on 15 mg. You can read a fuller breakdown of how Mounjaro pricing works by dose to understand what different stages of treatment typically cost. For the broader context of why this increase happened, the reasons behind the Mounjaro price rise are covered separately.

What a headline price often leaves out

When you see a monthly figure quoted (in a search result, a comparison site, or a social-media advert) it is worth pausing for thirty seconds to check whether that number includes everything you will actually pay. A quick look at the checkout summary before entering card details can save a real surprise.

Common additions that appear only at the end of a journey: an initial consultation fee (sometimes £30–£50), a separate prescription charge, a delivery fee per order, and aftercare costs if you need clinical advice between orders. Some services charge for dose-escalation reviews as a separate event. Others operate on a subscription basis, meaning your card is charged automatically each month unless you cancel actively. None of these additions are hidden in a dishonest sense (they are usually disclosed) but they are not always visible in the headline number used to attract your attention.

The MHRA and NHS England both emphasise that tirzepatide is a prescription-only medicine requiring ongoing clinical oversight, not a product you purchase once and manage alone. That oversight has a real cost. The question is whether it is bundled into what you see upfront or dripped in afterwards. A closer look at Mounjaro's monthly cost covers the full picture of what a realistic private spend looks like, including what is reasonable to ask any provider before committing.

Where nume sits, and why we are not the cheapest

We are deliberately not the lowest-priced option in this market. That is a choice, not an oversight. Our single price per treatment includes the consultation, the prescription, the medicine, and free next-working-day DPD delivery. There are no separate fees for aftercare, no charge for speaking to our team if you have a question between orders, and no subscription that runs quietly in the background. Every repeat order goes through a fresh clinical review by a GPhC-registered Independent Prescriber, a real person reads your case, not software processing a form.

Our pharmacy is registered with the General Pharmaceutical Council under premises number 9012878, which you can verify directly at the GPhC pharmacy register. Mounjaro is sourced through the licensed UK supply chain via Eli Lilly's authorised UK network. Current treatment pricing is shown on our treatment page, alongside what each plan covers. You will not find a different figure hiding further into a checkout.

If you want to understand how the NHS pricing picture sits alongside private options, NHS Mounjaro access and pricing explains what the phased rollout means and who currently qualifies. The short answer is that NHS eligibility remains tightly restricted for now, which is why most people exploring private treatment are doing so because the NHS route is not yet open to them.

Why 'cheapest' is the wrong test for a prescription medicine

The price increase has understandably sent people searching for lower-cost routes. That is a rational response. But for a prescription-only medicine like Mounjaro, the cheapest listing answers a different question from the one you actually need answered, which is: is this supply genuine, clinically supervised, and safe?

The MHRA has warned repeatedly about counterfeit weight-loss pens circulating online and through social media. In October 2025, enforcement teams raided an illicit UK manufacturing site in Northampton producing fake tirzepatide pens, and around 20 million doses of illegally traded weight-loss medicines (roughly £45 million street value) have been seized in recent enforcement operations. Fake pens have in some cases contained insulin. Prices significantly below the current private market, sellers offering supply without a prescription, and discount codes from unverified accounts are all recognised red flags. You can report suspect sellers at the MHRA's Yellow Card site.

A small saving on a monthly pen is not worth the clinical risk of unverified supply. A legitimate provider (verifiable on the GPhC register, prescribing only after proper assessment, sourcing through the authorised UK supply chain) is the baseline, not an optional extra. More on how Mounjaro costs are changing gives additional context if you are weighing your options. When you are ready to be assessed, start your free consultation with our prescribers.